Cell therapy is the use of living cells to treat or potentially cure a human disease or injury. Tissue Engineering (TE) is a medical field that focuses on restoring, maintaining, improving, or replacing damaged tissues and organs through a combination of scaffolds, cells, and biologically active molecules.
Highlights
The global Cell Therapy and Tissue Engineering market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Cell therapy is the use of living cells to treat or potentially cure a human disease or injury. Tissue Engineering (TE) is a medical field that focuses on restoring, maintaining, improving, or replacing damaged tissues and organs through a combination of scaffolds, cells, and biologically active molecules. Cell therapy, genetically modified cell therapy, gene therapy and tissue engineering are the four pillars of Regenerative Medicine (RM). These therapies have the potential to beneficially alter the quality of life and improve the health of patients with cell defects, genetic diseases, neurodegenerative diseases, tissue malignancies and other medical conditions.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cell Therapy and Tissue Engineering, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell Therapy and Tissue Engineering.
The Cell Therapy and Tissue Engineering market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cell Therapy and Tissue Engineering market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cell Therapy and Tissue Engineering companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Betalin Therapeutics
BioCardia, Inc
BioReliance Corporation
Biosolution Co.
Brainstorm Cell Therapeutics, Inc
MaxCyte, Inc
Medigene AG
MEDIPOST CO.
Mesoblast Limited
Miromatrix Medical, Inc.
MolMed S.p.A
Mustang Bio, Inc
NantKwest, Inc.
Neuralstem, Inc
NexImmune, Inc.
Nohla Therapeutics, Inc
ReNeuron Group plc
Richter-Helm BioLogics GmbH & Co. KG
RoosterBio, Inc
RoslinCT
Rubius Therapeutics, Inc.
Sangamo Therapeutics, Inc
Voyager Therapeutics, Inc
Waisman Biomanufacturing
WindMIL Therapeutics, Inc.
Wuxi App Tec, Inc.
ReNeuron Group plc
Richter-Helm BioLogics GmbH & Co. KG
RoosterBio, Inc
RoslinCT
Segment by Type
Cell Therapy
Tissue Engineering
Segment by Application
Cell Defects
Genetic Diseases
Neurodegenerative Diseases
Tissue Malignancies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell Therapy and Tissue Engineering companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cell Therapy and Tissue Engineering 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cell Therapy
1.2.3 Tissue Engineering
1.3 麻豆原创 by Application
1.3.1 Global Cell Therapy and Tissue Engineering 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cell Defects
1.3.3 Genetic Diseases
1.3.4 Neurodegenerative Diseases
1.3.5 Tissue Malignancies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell Therapy and Tissue Engineering 麻豆原创 Perspective (2018-2029)
2.2 Cell Therapy and Tissue Engineering Growth Trends by Region
2.2.1 Global Cell Therapy and Tissue Engineering 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cell Therapy and Tissue Engineering Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cell Therapy and Tissue Engineering Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cell Therapy and Tissue Engineering 麻豆原创 Dynamics
2.3.1 Cell Therapy and Tissue Engineering Industry Trends
2.3.2 Cell Therapy and Tissue Engineering 麻豆原创 Drivers
2.3.3 Cell Therapy and Tissue Engineering 麻豆原创 Challenges
2.3.4 Cell Therapy and Tissue Engineering 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell Therapy and Tissue Engineering Players by Revenue
3.1.1 Global Top Cell Therapy and Tissue Engineering Players by Revenue (2018-2023)
3.1.2 Global Cell Therapy and Tissue Engineering Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cell Therapy and Tissue Engineering 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell Therapy and Tissue Engineering Revenue
3.4 Global Cell Therapy and Tissue Engineering 麻豆原创 Concentration Ratio
3.4.1 Global Cell Therapy and Tissue Engineering 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell Therapy and Tissue Engineering Revenue in 2022
3.5 Cell Therapy and Tissue Engineering Key Players Head office and Area Served
3.6 Key Players Cell Therapy and Tissue Engineering Product Solution and Service
3.7 Date of Enter into Cell Therapy and Tissue Engineering 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell Therapy and Tissue Engineering Breakdown Data by Type
4.1 Global Cell Therapy and Tissue Engineering Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cell Therapy and Tissue Engineering Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cell Therapy and Tissue Engineering Breakdown Data by Application
5.1 Global Cell Therapy and Tissue Engineering Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cell Therapy and Tissue Engineering Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cell Therapy and Tissue Engineering 麻豆原创 Size (2018-2029)
6.2 North America Cell Therapy and Tissue Engineering 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2018-2023)
6.4 North America Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell Therapy and Tissue Engineering 麻豆原创 Size (2018-2029)
7.2 Europe Cell Therapy and Tissue Engineering 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell Therapy and Tissue Engineering 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cell Therapy and Tissue Engineering 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cell Therapy and Tissue Engineering 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cell Therapy and Tissue Engineering 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell Therapy and Tissue Engineering 麻豆原创 Size (2018-2029)
9.2 Latin America Cell Therapy and Tissue Engineering 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell Therapy and Tissue Engineering 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cell Therapy and Tissue Engineering 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cell Therapy and Tissue Engineering 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Betalin Therapeutics
11.1.1 Betalin Therapeutics Company Detail
11.1.2 Betalin Therapeutics Business Overview
11.1.3 Betalin Therapeutics Cell Therapy and Tissue Engineering Introduction
11.1.4 Betalin Therapeutics Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.1.5 Betalin Therapeutics Recent Development
11.2 BioCardia, Inc
11.2.1 BioCardia, Inc Company Detail
11.2.2 BioCardia, Inc Business Overview
11.2.3 BioCardia, Inc Cell Therapy and Tissue Engineering Introduction
11.2.4 BioCardia, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.2.5 BioCardia, Inc Recent Development
11.3 BioReliance Corporation
11.3.1 BioReliance Corporation Company Detail
11.3.2 BioReliance Corporation Business Overview
11.3.3 BioReliance Corporation Cell Therapy and Tissue Engineering Introduction
11.3.4 BioReliance Corporation Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.3.5 BioReliance Corporation Recent Development
11.4 Biosolution Co.
11.4.1 Biosolution Co. Company Detail
11.4.2 Biosolution Co. Business Overview
11.4.3 Biosolution Co. Cell Therapy and Tissue Engineering Introduction
11.4.4 Biosolution Co. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.4.5 Biosolution Co. Recent Development
11.5 Brainstorm Cell Therapeutics, Inc
11.5.1 Brainstorm Cell Therapeutics, Inc Company Detail
11.5.2 Brainstorm Cell Therapeutics, Inc Business Overview
11.5.3 Brainstorm Cell Therapeutics, Inc Cell Therapy and Tissue Engineering Introduction
11.5.4 Brainstorm Cell Therapeutics, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.5.5 Brainstorm Cell Therapeutics, Inc Recent Development
11.6 MaxCyte, Inc
11.6.1 MaxCyte, Inc Company Detail
11.6.2 MaxCyte, Inc Business Overview
11.6.3 MaxCyte, Inc Cell Therapy and Tissue Engineering Introduction
11.6.4 MaxCyte, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.6.5 MaxCyte, Inc Recent Development
11.7 Medigene AG
11.7.1 Medigene AG Company Detail
11.7.2 Medigene AG Business Overview
11.7.3 Medigene AG Cell Therapy and Tissue Engineering Introduction
11.7.4 Medigene AG Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.7.5 Medigene AG Recent Development
11.8 MEDIPOST CO.
11.8.1 MEDIPOST CO. Company Detail
11.8.2 MEDIPOST CO. Business Overview
11.8.3 MEDIPOST CO. Cell Therapy and Tissue Engineering Introduction
11.8.4 MEDIPOST CO. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.8.5 MEDIPOST CO. Recent Development
11.9 Mesoblast Limited
11.9.1 Mesoblast Limited Company Detail
11.9.2 Mesoblast Limited Business Overview
11.9.3 Mesoblast Limited Cell Therapy and Tissue Engineering Introduction
11.9.4 Mesoblast Limited Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.9.5 Mesoblast Limited Recent Development
11.10 Miromatrix Medical, Inc.
11.10.1 Miromatrix Medical, Inc. Company Detail
11.10.2 Miromatrix Medical, Inc. Business Overview
11.10.3 Miromatrix Medical, Inc. Cell Therapy and Tissue Engineering Introduction
11.10.4 Miromatrix Medical, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.10.5 Miromatrix Medical, Inc. Recent Development
11.11 MolMed S.p.A
11.11.1 MolMed S.p.A Company Detail
11.11.2 MolMed S.p.A Business Overview
11.11.3 MolMed S.p.A Cell Therapy and Tissue Engineering Introduction
11.11.4 MolMed S.p.A Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.11.5 MolMed S.p.A Recent Development
11.12 Mustang Bio, Inc
11.12.1 Mustang Bio, Inc Company Detail
11.12.2 Mustang Bio, Inc Business Overview
11.12.3 Mustang Bio, Inc Cell Therapy and Tissue Engineering Introduction
11.12.4 Mustang Bio, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.12.5 Mustang Bio, Inc Recent Development
11.13 NantKwest, Inc.
11.13.1 NantKwest, Inc. Company Detail
11.13.2 NantKwest, Inc. Business Overview
11.13.3 NantKwest, Inc. Cell Therapy and Tissue Engineering Introduction
11.13.4 NantKwest, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.13.5 NantKwest, Inc. Recent Development
11.14 Neuralstem, Inc
11.14.1 Neuralstem, Inc Company Detail
11.14.2 Neuralstem, Inc Business Overview
11.14.3 Neuralstem, Inc Cell Therapy and Tissue Engineering Introduction
11.14.4 Neuralstem, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.14.5 Neuralstem, Inc Recent Development
11.15 NexImmune, Inc.
11.15.1 NexImmune, Inc. Company Detail
11.15.2 NexImmune, Inc. Business Overview
11.15.3 NexImmune, Inc. Cell Therapy and Tissue Engineering Introduction
11.15.4 NexImmune, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.15.5 NexImmune, Inc. Recent Development
11.16 Nohla Therapeutics, Inc
11.16.1 Nohla Therapeutics, Inc Company Detail
11.16.2 Nohla Therapeutics, Inc Business Overview
11.16.3 Nohla Therapeutics, Inc Cell Therapy and Tissue Engineering Introduction
11.16.4 Nohla Therapeutics, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.16.5 Nohla Therapeutics, Inc Recent Development
11.17 ReNeuron Group plc
11.17.1 ReNeuron Group plc Company Detail
11.17.2 ReNeuron Group plc Business Overview
11.17.3 ReNeuron Group plc Cell Therapy and Tissue Engineering Introduction
11.17.4 ReNeuron Group plc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.17.5 ReNeuron Group plc Recent Development
11.18 Richter-Helm BioLogics GmbH & Co. KG
11.18.1 Richter-Helm BioLogics GmbH & Co. KG Company Detail
11.18.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview
11.18.3 Richter-Helm BioLogics GmbH & Co. KG Cell Therapy and Tissue Engineering Introduction
11.18.4 Richter-Helm BioLogics GmbH & Co. KG Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.18.5 Richter-Helm BioLogics GmbH & Co. KG Recent Development
11.19 RoosterBio, Inc
11.19.1 RoosterBio, Inc Company Detail
11.19.2 RoosterBio, Inc Business Overview
11.19.3 RoosterBio, Inc Cell Therapy and Tissue Engineering Introduction
11.19.4 RoosterBio, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.19.5 RoosterBio, Inc Recent Development
11.20 RoslinCT
11.20.1 RoslinCT Company Detail
11.20.2 RoslinCT Business Overview
11.20.3 RoslinCT Cell Therapy and Tissue Engineering Introduction
11.20.4 RoslinCT Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.20.5 RoslinCT Recent Development
11.21 Rubius Therapeutics, Inc.
11.21.1 Rubius Therapeutics, Inc. Company Detail
11.21.2 Rubius Therapeutics, Inc. Business Overview
11.21.3 Rubius Therapeutics, Inc. Cell Therapy and Tissue Engineering Introduction
11.21.4 Rubius Therapeutics, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.21.5 Rubius Therapeutics, Inc. Recent Development
11.22 Sangamo Therapeutics, Inc
11.22.1 Sangamo Therapeutics, Inc Company Detail
11.22.2 Sangamo Therapeutics, Inc Business Overview
11.22.3 Sangamo Therapeutics, Inc Cell Therapy and Tissue Engineering Introduction
11.22.4 Sangamo Therapeutics, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.22.5 Sangamo Therapeutics, Inc Recent Development
11.23 Voyager Therapeutics, Inc
11.23.1 Voyager Therapeutics, Inc Company Detail
11.23.2 Voyager Therapeutics, Inc Business Overview
11.23.3 Voyager Therapeutics, Inc Cell Therapy and Tissue Engineering Introduction
11.23.4 Voyager Therapeutics, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.23.5 Voyager Therapeutics, Inc Recent Development
11.24 Waisman Biomanufacturing
11.24.1 Waisman Biomanufacturing Company Detail
11.24.2 Waisman Biomanufacturing Business Overview
11.24.3 Waisman Biomanufacturing Cell Therapy and Tissue Engineering Introduction
11.24.4 Waisman Biomanufacturing Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.24.5 Waisman Biomanufacturing Recent Development
11.25 WindMIL Therapeutics, Inc.
11.25.1 WindMIL Therapeutics, Inc. Company Detail
11.25.2 WindMIL Therapeutics, Inc. Business Overview
11.25.3 WindMIL Therapeutics, Inc. Cell Therapy and Tissue Engineering Introduction
11.25.4 WindMIL Therapeutics, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.25.5 WindMIL Therapeutics, Inc. Recent Development
11.26 Wuxi App Tec, Inc.
11.26.1 Wuxi App Tec, Inc. Company Detail
11.26.2 Wuxi App Tec, Inc. Business Overview
11.26.3 Wuxi App Tec, Inc. Cell Therapy and Tissue Engineering Introduction
11.26.4 Wuxi App Tec, Inc. Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.26.5 Wuxi App Tec, Inc. Recent Development
11.27 ReNeuron Group plc
11.27.1 ReNeuron Group plc Company Detail
11.27.2 ReNeuron Group plc Business Overview
11.27.3 ReNeuron Group plc Cell Therapy and Tissue Engineering Introduction
11.27.4 ReNeuron Group plc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.27.5 ReNeuron Group plc Recent Development
11.28 Richter-Helm BioLogics GmbH & Co. KG
11.28.1 Richter-Helm BioLogics GmbH & Co. KG Company Detail
11.28.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview
11.28.3 Richter-Helm BioLogics GmbH & Co. KG Cell Therapy and Tissue Engineering Introduction
11.28.4 Richter-Helm BioLogics GmbH & Co. KG Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.28.5 Richter-Helm BioLogics GmbH & Co. KG Recent Development
11.29 RoosterBio, Inc
11.29.1 RoosterBio, Inc Company Detail
11.29.2 RoosterBio, Inc Business Overview
11.29.3 RoosterBio, Inc Cell Therapy and Tissue Engineering Introduction
11.29.4 RoosterBio, Inc Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.29.5 RoosterBio, Inc Recent Development
11.30 RoslinCT
11.30.1 RoslinCT Company Detail
11.30.2 RoslinCT Business Overview
11.30.3 RoslinCT Cell Therapy and Tissue Engineering Introduction
11.30.4 RoslinCT Revenue in Cell Therapy and Tissue Engineering Business (2018-2023)
11.30.5 RoslinCT Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Betalin Therapeutics
BioCardia, Inc
BioReliance Corporation
Biosolution Co.
Brainstorm Cell Therapeutics, Inc
MaxCyte, Inc
Medigene AG
MEDIPOST CO.
Mesoblast Limited
Miromatrix Medical, Inc.
MolMed S.p.A
Mustang Bio, Inc
NantKwest, Inc.
Neuralstem, Inc
NexImmune, Inc.
Nohla Therapeutics, Inc
ReNeuron Group plc
Richter-Helm BioLogics GmbH & Co. KG
RoosterBio, Inc
RoslinCT
Rubius Therapeutics, Inc.
Sangamo Therapeutics, Inc
Voyager Therapeutics, Inc
Waisman Biomanufacturing
WindMIL Therapeutics, Inc.
Wuxi App Tec, Inc.
ReNeuron Group plc
Richter-Helm BioLogics GmbH & Co. KG
RoosterBio, Inc
RoslinCT
听
听
*If Applicable.
